Discordant hormone receptor and human epidermal growth factor receptor 2 status in bone metastases compared to primary breast cancer
- PMID: 23327413
- DOI: 10.3109/0284186X.2012.754990
Discordant hormone receptor and human epidermal growth factor receptor 2 status in bone metastases compared to primary breast cancer
Abstract
Background: In patients with metastatic breast cancer, the evaluation of the biological characteristics of metastatic bone deposits may be a valuable adjunct in clinical practice. We assessed the discordance in expression levels for estrogen receptor (ER), progesterone receptor (PgR) and human epidermal growth factor receptor 2 (HER2) between primary tumor and bone metastases and its clinical impact on patient management.
Material and methods: We retrospectively reviewed 363 CT-guided bone biopsies performed from January 1997 to December 2009. The proportions of ER, PgR and HER2 positive tumors at primary diagnosis and bone metastases, determined by IHC and/or FISH, were compared using McNemar's test. The impact of the biopsy reassessment on treatment choice was evaluated with Fisher's exact test.
Results: We selected 109 metastatic breast cancer patients with histologically confirmed bone metastases. Among 107 assessable patients the overall discordance rate was detected in 22 (20.5%) and in 47 (43.9%) patients for ER and PgR, respectively, and in six of 86 assessable patients (6.9%) for HER2 status. The indication to change endocrine therapy occurred in 62% and 30% of patients with ER discordance and ER concordance, respectively (p = 0.01). The indication to change targeted therapy occurred in 67% and 8% of patients with HER2 discordance and HER2 concordance, respectively (p = 0.002).
Conclusions: We confirm that biopsy of metastases, including bone metastases, for reassessment of biology should be considered, since it is likely to impact on treatment choice.
Similar articles
-
Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases.J BUON. 2012 Apr-Jun;17(2):277-83. J BUON. 2012. PMID: 22740206
-
Hormonal receptor, human epidermal growth factor receptor-2, and Ki67 discordance between primary breast cancer and paired metastases: clinical impact.Oncology. 2013;84(3):150-7. doi: 10.1159/000345795. Epub 2012 Dec 19. Oncology. 2013. PMID: 23257904
-
A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases.Eur J Cancer. 2014 Jan;50(2):277-89. doi: 10.1016/j.ejca.2013.10.004. Epub 2013 Nov 21. Eur J Cancer. 2014. PMID: 24269135
-
Hormone Receptor Status and HER2 Expression in Primary Breast Cancer Compared With Synchronous Axillary Metastases or Recurrent Metastatic Disease.Clin Breast Cancer. 2015 Oct;15(5):307-12. doi: 10.1016/j.clbc.2015.03.010. Epub 2015 Mar 25. Clin Breast Cancer. 2015. PMID: 25922284 Review.
-
Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer.Cancer Treat Rev. 2011 Oct;37(6):422-30. doi: 10.1016/j.ctrv.2010.11.006. Epub 2010 Dec 21. Cancer Treat Rev. 2011. PMID: 21177040 Review.
Cited by
-
Interrogating Estrogen Signaling Pathways in Human ER-Positive Breast Cancer Cells Forming Bone Metastases in Mice.Endocrinology. 2024 Apr 29;165(6):bqae038. doi: 10.1210/endocr/bqae038. Endocrinology. 2024. PMID: 38715255
-
Dynamic whole-body [18F]FES PET/CT increases lesion visibility in patients with metastatic breast cancer.EJNMMI Res. 2024 Mar 4;14(1):24. doi: 10.1186/s13550-024-01080-y. EJNMMI Res. 2024. PMID: 38436824 Free PMC article.
-
Macrophages Promote Subtype Conversion and Endocrine Resistance in Breast Cancer.Cancers (Basel). 2024 Feb 5;16(3):678. doi: 10.3390/cancers16030678. Cancers (Basel). 2024. PMID: 38339428 Free PMC article.
-
ER status conversion and subsequent treatment: an assessment of negative ER expression detected by 18F-FES PET in metastatic breast cancer patients with ER-positive primary tumors.Ther Adv Med Oncol. 2023 Dec 15;15:17588359231216093. doi: 10.1177/17588359231216093. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 38107829 Free PMC article.
-
Efficacy of a HER2-Targeted Thorium-227 Conjugate in a HER2-Positive Breast Cancer Bone Metastasis Model.Cancers (Basel). 2023 Jun 29;15(13):3419. doi: 10.3390/cancers15133419. Cancers (Basel). 2023. PMID: 37444529 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous